Featured News
1.3KWire StoriesKyowa Kirin Receives Positive CHMP Opinion for Use of CRYSVITA® ?(burosumab) for the Treatment of Tumour-Induced Osteomalacia (TIO)
CRYSVITA could offer access to the first biologic treatment for EU patients with TIO who cannot undergo surgical removal of tumours TOKYO–(BUSINESS...
- 580Wire Stories
Dr. Reddy’s Laboratories Announces the Acquisition of an Injectable Product Portfolio from Eton Pharma
HYDERABAD, India & PRINCETON, N.J.–(BUSINESS WIRE)–$RDY #Acquisition–Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY, along with its subsidiaries...
- 475Wire Stories
Locix’s Warehouse Intelligence Solution Deployment Named a Recipient of Supply & Demand Chain Executive’s Top Supply Chain Projects Awards
This award spotlights successful and innovative transformation projects that deliver bottom-line value to small, medium, and large enterprises across a range of...
- 515Wire Stories
Propanc Biopharma Announces No Immediate Plans for Reverse Stock Split
Company Filed a Definitive Information Statement Under Section 14C of the Exchange Act MELBOURNE, Australia–(BUSINESS WIRE)–Propanc Biopharma, Inc. (OTCQB: PPCB) (“Propanc” or...
- 570Wire Stories
Entegris and CMC Materials Receive China Antitrust Clearance for Pending Acquisition
Transaction Expected to Close on July 6, 2022 BILLERICA, Mass. & AURORA, Ill.–(BUSINESS WIRE)–Entegris, Inc. (NASDAQ: ENTG) and CMC Materials, Inc. (NASDAQ:...
- 534Wire Stories
Growing Number of CAGR of 4.3% from 2022 to 2030, mTOR Inhibitors Market Size to USD 9,445 Mn by 2030 Report By Acumen Research and Consulting
Acumen Research and Consulting recently published report titled “mTOR Inhibitors Market Size, Share, Analysis Report and Region Forecast, 2022 – 2030” LOS...
- 482Wire Stories
Biolexis and Akston Biosciences Announce Encouraging Top-Line Results from Phase II/III Trial of their Thermostable 2nd Gen COVID-19 Vaccine
Results of 100 subjects bridging study and 1,500 subjects placebo-controlled trial of Akston’s AKS-452 announced. Interim analysis shows a 91% seroconversion rate....
- 592Wire Stories
Biolexis and Akston Biosciences Announce Encouraging Top-Line Results from Phase II/III Trial of their Thermostable 2nd Gen COVID-19 Vaccine
Results of 100 subjects bridging study and 1,500 subjects placebo-controlled trial of Akston’s AKS-452 announced. Interim analysis shows a 91% seroconversion rate....
- 528Wire Stories
Thailand Telecoms, Mobile and Broadband Market Analyses Report 2022 – ResearchAndMarkets.com
DUBLIN–(BUSINESS WIRE)–The “Thailand – Telecoms, Mobile and Broadband – Statistics and Analyses” report has been added to ResearchAndMarkets.com’s offering. Thailand sees boost...
- 511Wire Stories
Thailand Telecoms, Mobile and Broadband Market Analyses Report 2022 – ResearchAndMarkets.com
DUBLIN–(BUSINESS WIRE)–The “Thailand – Telecoms, Mobile and Broadband – Statistics and Analyses” report has been added to ResearchAndMarkets.com’s offering. Thailand sees boost...
- 468Wire Stories
GTJAI Received 16 Awards from Institutional Investor including “Most Honored Company”
HONG KONG–(BUSINESS WIRE)–Guotai Junan International Holdings Limited (“GTJAI” or the “Company”, Stock Code: 1788.HK) announced that Institutional Investor, a globally renowned financial...
